Oncorus, Inc.

OTCPK:ONCR Stock Report

Market Cap: US$3.3m

Oncorus Dividends and Buybacks

Dividend criteria checks 0/6

Oncorus does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-3.8%

Buyback Yield

Total Shareholder Yield-3.8%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Seeking Alpha • Aug 04

Oncorus GAAP EPS of -$0.74 misses by $0.02

Oncorus press release (NASDAQ:ONCR): Q2 GAAP EPS of -$0.74 misses by $0.02. Additional clinical data from ONCR-177 surface lesion monotherapy and combination expansion cohorts expected in second half of 2022 Company remains on track to submit IND for ONCR-021 in mid-2023 Ended quarter with $100.2 million in cash and cash equivalents to support next-generation viral immunotherapy pipeline
Analysis Article • Oct 14

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jul 09

Oncorus: Shares Look Cheap As First Oncolytic Viral Therapy Enters Clinic

Oncorus shares have been in steady decline since nearly doubling in value less than six months after the company's October 2020 IPO. Current trading price of $13 is slightly under the $15 IPO price, but the biotech has just entered the clinic with its first viral oncolytic therapy, ONCR-177. The therapy uses the herpes simplex virus to gain entry to tumor cells, where it unleashes five different immunomodulatory payloads. The heavily engineered therapy has numerous questions to answer in the clinic. In preclinical mouse models, the safety and potency profile of ONCR-177 looked strong. Markets including melanoma, breast and colorectal cancer are in play for Oncorus, and longer term, a synthetics platform will target NSCLC and SCLC. Given its opportunity and technology, a market cap
Analysis Article • May 05

Oncorus (NASDAQ:ONCR) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 26

What Kind Of Shareholders Own Oncorus, Inc. (NASDAQ:ONCR)?

A look at the shareholders of Oncorus, Inc. ( NASDAQ:ONCR ) can tell us which group is most powerful. Generally...
Analysis Article • Jan 04

We're Not Very Worried About Oncorus' (NASDAQ:ONCR) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if ONCR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ONCR's dividend payments have been increasing.

Dividend Yield vs Market

Oncorus Dividend Yield vs Market
How does ONCR dividend yield compare to the market?
SegmentDividend Yield
Company (ONCR)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.1%
Analyst forecast (ONCR) (up to 3 years)n/a

Notable Dividend: Unable to evaluate ONCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ONCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate ONCR's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ONCR has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/03 20:47
End of Day Share Price 2023/12/29 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncorus, Inc. is covered by 6 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Matthew BarcusChardan Capital Markets, LLC
Joshua SchimmerEvercore ISI
Swayampakula RamakanthH.C. Wainwright & Co.